肝动脉推注华蟾素联合热灌注化疗治疗原发性肝癌的疗效

doi:10.3969/j.issn.1671-7171.2019.07.012

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (0 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要 【目的】探讨华蟾素肝动脉推注联合热灌注化疗治疗原发性肝癌的临床疗效。【方法】76例原发性肝癌患者随机分为两组,各38例。对照组采取经动脉热灌注化疗后经动脉化疗栓塞(TACE),观察组采取华蟾素肝动脉推注联合热灌注化疗后TACE,均治疗3次,每次间隔1个月。比较两组疗效、不良反应发生率及无进展生存期(PFS)、总生存期(OS)。【结果】观察组疾病控制率为63.16%(24/38),高于对照组的41.67%(20/38),但两组之间比较差异无显著性(P>0.05)。观察组疼痛发生率为36.84%(14/38),显著低于对照组的63.16%(24/38),且两组相比较差异有显著性(P<0.05)。观察组PFS为(12.01±2.89)个月,OS为(19.32±5.48)个月,均显著高于对照组的(10.03±3.00)个月和(15.43±4.82)个月,且两组相比较差异均有显著性(均P<0.05)。【结论】华蟾素肝动脉推注联合热灌注化疗治疗原发性肝癌的抗肿瘤效果更佳,患者生存期得以延长且疼痛减轻,值得临床推广。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	蔡向阳
	张东

关键词 ：华蟾蜍毒素/药理学, 化学疗法, 肿瘤, 局部灌注, 肝肿瘤/药物疗法

Abstract：【Objective】To investigate the clinical effect of cinobufotalin injection through hepatic artery combined with hyperthermic perfusion chemotherapy in the treatment of primary hepatocellular carcinoma. 【Methods】Seventy-six patients with primary liver cancer were randomly divided into two groups, 38 cases each. The control group received transcatheter arterial chemoembolization (TACE) after transcatheter arterial infusion chemotherapy, while the observation group received hepatic artery injection of cinobufotalin combined with transcatheter arterial infusion chemotherapy (TACE) three times, one month apart. The efficacy, incidence of adverse reactions, PFS and OS of the two groups were compared.【Results】The disease control rate of the observation group was 63.16% (24/38), higher than that of the control group 41.67% (20/38), but there was no significant difference between the two groups (P>0.05). The incidence of pain in the observation group was 36.84% (14/38), significantly lower than that in the control group 63.16% (24/38), and there was a significant difference between the two groups (P<0.05). The PFS and OS of the observation group were (12.01±2.89) months and (19.32±5.48) months, which were significantly higher than those of the control group (10.03±3.00) months and (15.43 ±4.82) months, and there were significant differences between the two groups (all P<0.05). 【Conclusion】The anti-tumor effect of cinobufotalin intrahepatic artery injection combined with hyperthermic perfusion chemotherapy for primary hepatocellular carcinoma is better, the survival time of patients is prolonged and the pain is alleviated, which is worthy of clinical promotion.

Key words： CINOBUFAGIN/TU Chemotherapy,Cancer,Regional Perfusion Liver Neoplasms/DT

收稿日期: 2019-02-27

PACS:

R735.7

引用本文:

蔡向阳, 张东. 肝动脉推注华蟾素联合热灌注化疗治疗原发性肝癌的疗效[J]. 医学临床研究, 2019, 36(7): 1282-1284.
CAI Xiang-yang, ZHANG Dong. Clinical effect of Hepatic Artery Injection of Cinobufotalin Combined with Hyperthermic Perfusion Chemotherapy in the Treatment of Primary Hepatocellular Carcinoma. JOURNAL OF CLINICAL RESEARCH, 2019, 36(7): 1282-1284.

链接本文:

http://journal07.magtech.org.cn/yxlcyj/CN/10.3969/j.issn.1671-7171.2019.07.012 或 http://journal07.magtech.org.cn/yxlcyj/CN/Y2019/V36/I7/1282